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two strong precipitates in the betazone. And diffusing against serum of the same individual 
they yield only one precipitate. Fibrinogen is the difference between plasma and serum, thus 
the comparison of the two last immunoelectrophoreses demonstrates that the antileukocyte sera 
are strongly fibrinogen precipitating. 
On this statement we inverted the immunological reasoning and started to look for an anti- 
leukocyte effect of an antifibrinogen serum. It was obtained by immunising rabbits tolerant to 
serum with plasma. It was not absorbed, thus a rather specific and pure antifibrinogen serum. 
We have applied it on the same leukocyte mixture aforementioned and observed a strong leuko- 
agglutination. The very few cells non-agglutinated were mostly polymorphonuclear, that is to 
say, the antifibrinogen serum was principally antilymphocyte. Of course, we have checked that 
leukoagglutination is neither a general feature for a normal rabbit serum nor for an antiserum 
even a strong one. 
In summary antileukocyte serum is antifibrinogen and antifibrinogen serum seems to be 
antileukocyte. We wish to provoque other remarks on the problem of the specificity of anti- 
leukocyte and antilymphocyte sera. Their beneficial action on graft tolerance may not be so 
simple as it was firstly hyothesised. 
The Prospects of Successful Liver Transplantation in Man 
With Special Emphasis on the Possible Use of Antilymphoid Globulin' 
By Th. E. STARZL, DenverICol., Th. L. MARCHIORO, DenverICol., L. BRETTSCHNEIDER, 
DenverICol., Y. IWASAKI, Chiba (Japan) 
That homotransplantation of the liver is a feasible procedure is already known. In the 
spring and summer of 1964, a large series of orthotopic hepatic transplantations were 
carried out in dogs, using homografts obtained from nonrelated mongrel donors. The 
only measure taken to prevent rejection was the administration of azathioprine, which 
is still the single best immunosuppressive agent known, but which is a drug that is mar- 
kedly hepatotoxic in dogs. In spite of the latter handicap, survival was at least as consi- 
stent in these experiments (16) as can be obtained with comparable treatment after 
canine renal homotransplantation. Four of the dogs are still alive, a convincing demon- 
stration, inasmuch as their own livers were totally excised at the time of the original 
operation. All 4 of these animals received azathioprine for only 4 months. Since its dis- 
continuation, they have received no therapy whatsoever. 
Important information has also accrued on the alternative method of auxiliary liver 
transplantation, an operation which does not involve recipient hepatectomy. The physio- 
logic prerequisites for the successful use of this procedure have been defined as the 
result of studies in dogs which demonstrated a metabolic competition between the ho- 
mograft and the autologous liver (9). The capacity for function which either liver pos- 
sesses determines the extent to which the other organ is ,,starvedc'. Presumably, the 
more severe the damage to the host liver, the less hostile the environment would be for 
the homograft. The relative advantages which the coexistent organs enjoy can be mani- 
pulated by the method selected for revascularization of the homograft or by the perfor- 
mance or omission of host portacaval shunt (4, 9, 20). 
* Aided by United States Public Health Service grants AM 06283, AM 06344, HE 07735, 
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In spite of this progress, all efforts to apply hepatic homotransplantation for the 
treatment of human liver disease have failed. The reasons have been multiple. The 
technical procedures of either orthotopic or auxiliary transplantation were particularly 
difficult in patients with hepatic disease who had poor liver function, portal hyperten- 
sion, and coagulation disorders. The problem of obtaining well preserved cadaveric 
organs was a serious one. Even after satisfactory operations, a high incidence of hyper- 
coagulability was encountered which led to pulmonary embolization from 1 to 3 weeks 
later. Frequent gastrointestinal ulceration and hemorrhage were noted. All of these 
problems as well as others have been extensively discussed in recent reviews (17, 18) 
and will not be treated further here except to say that none seems to constitute an in- 
surmountable obstacle. 
Instead, the single most unsatisfactory element of clinical care has concerned the 
immunosuppressive regimen. The combination of azathioprine and high doses of pred- 
nisone, which is usually required to control rejection after homotransplantation of either 
renal or hepatic homografts obtained from nonrelated donors, has been poorly tolerated 
by liver recipients. All patients, who survived for more than a few days after both 
auxiliary or orthotopic procedures, developed infectious complications. Pneumonitis 
was almost invariable. There was difficulty with dose control of azathioprine, probably 
because this agent has an important hepatic pathway of metabolism. With the reduced 
liver function at the time of rejection, several recipients developed bone marrow de- 
pression including a patient whose survival of 34 days has been the longest yet attained (4). 
It has become increasingly clear that there will not be a reasonable hope of long-term 
success until means are found to reduce the need for such dangerous immunosuppres- 
sion. 
There are 2 possible ways in which this objective can be achieved. The first is to per- 
fect methods of histocompatibility matching between recipients and prospective donors. 
One such antigen matching method, developed by Dr. PAUL TERASAKI of LOS Angeles, 
has been tested clinically in cases of renal homotransplantation. By selecting nonrelated 
donors on the basis of the best possible antigen match, it was possible to appreciably 
increase survival (18). Nevertheless, the mortality of 37 O l d  in the first year as well as the 
morbidity in those who survived were unacceptable. 
The alternative solution would be to develop better methods to prevent or mitigate 
rejection. The most promising new agents amongst the many recently evaluated have 
been antilymphoid serum or its derivatives. Although the potential immunosuppressive 
value of such substances has been known for a number of years, WOODRUFF (22) and 
WAKSMAN (21) were the first to suggest their use in transplantation. Since then, a num- 
ber of valuable confirmatory reports have been published (2, 6-8, 11-13, 23, 24) dea- 
ling with skin graft test systems in inbred rodents. For the past year and a half, much 
of the effort in our laboratory has been devoted to the development and testing of 
various antilymphoid products for protection of whole organs in the outbred canine 
and human populations. Similar efforts have been made by ABAZA (1) and MITCHELL (10) 
and their associates. 
Preparation of Antilymphoid Agents 
Twelve horses were immunized subcutaneously with lymphoid tissue, obtained from 
dog lyrnphnodes or spleens in 10 cases, and from cadaveric human lymphnodes, thy- 
muses or spleens in the other 2. Each horse received tissues from 10 to 40 donors. The 
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equine antibody response was monitored by the ability of the horse serum to aggluti- 
nate or to lyse dog or human white cells. There was considerable variability in the 
effect of the serum products upon the leukocytes of different tested members of the 
species which had been used for immunization, suggesting some individual specificity 
of the horse antibodies (15). 
Although the details of immunization and of the subsequent absorption and purifica- 
tion of the horse plasma or serum have been fully described (5), a few comments are 
pertinent. First, the most important factor in obtaining a potent horse antibody response 
is the cell dose as shown in Figure 1. In this ease, 0.18 to 1.4 billion subcutaneous 
human lymphocytes were given for several months. The leukoagglutinin titer rose to 
1 : 32. Subsequently, when 10 to 50 times more splenic lymphocytes were administered 
per injection, the titer quickly rose to 1 : 16,000. When large doses were used from the 
beginning, high titers could be reached in 20 to 75 days. 
TIME ' Y  DAYS 
Fig. 1 Effect of immunizing dose upon the leukoagglutinin titer of a horse inoculated with 
cadaveric human lymphoid tissue. Note that the rise in titer was very modest during the first 
3 months, during which time small doses of cells were used. When the quantitity of antigen was 
increased by the use of spleen cells. abrupt increases in titer were observed within a few days. 
(By permission of Surgery, Gynecology iL Obstetrics, 124 [1967], 1) 
The plasma prepared from the horse blood was toxic when given to dogs intraperi- 
toneally, causing the death of 11 of 36 animals within 15 days. Acute anemia was in- 
variable, which was apparently due at least in part to hemagglutinins which had deve- 
loped against canine red cells. Subsequently, it was found that both the anemia and the 
mortality could be eliminated by absorbing the dog plasma (or serum) with dog red cell 
pack until all hemagglutinins were removed, and by further absorption with pooled 
dog plasma (5). Neither procedure affected the leukoagglutinin titer. 
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A number of studies were performed to identify the anti-leukocyte antibody em- 
ploying chromatography with the DEAE cellulose column, electrophoresis and immuno- 
electrophoresis (5). An analysis of horse serum containing strong antihuman activity is 
shown in Figure 2. The leukoagglutinating antibody was located in the gamma G and 
T-equine globulin fractions probably with an additional small component in the beta 
globulin. I t  is probable that chromatographic separation will be a useful commercial 
method to separate such globulin for therapeutic use. With a pH of 6, and a phosphate 
buffer of 0.05, 60OIo of the antibody activity can be  retained. 
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Fig. 2 Studies of the leukoagglutinin-containing fractions in antihumanlymphoid serum emp- 
loying column chromatography, electrophoresis, and immunoelectrophoresis. The various eluates 
from the DEAE cellulose column were analyzed spectrophotometrically for protein content 
(expressed as optical density), and the presence or absence of leukoagglutinins determined for 
each collection tube. The electrophoresis and immunoelectrophoresis permitted relatively com- 
plete classification of the active immunoglobulins. (By permission of S u r g e ~ y ,  Gynecology rL. 
Obstetrics, 124 [1967], 1) 
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However, partly for practical purposes of bulk preparation, the alternative technic 
of double or quadruple ammonium sulphate precipitation was used to extract raw 
gobulin for testing. The quality of the product obtained by this method can be seen in 
Figure 3. 
Unabsorbed immune plasma or serum, or globulin removed after absorption of this 
serum all produced lymphopenia in dogs when injected intraperitoneally, intravenously 
or subcutaneously (Fig. 4), compared to an absence of this effect when normal horse 
serum was employed. There is little reason, however, to infer that the responsible 
equine antibodies have an immunologically specific action against these target cells. 
The Prospebts of Successful Liver Transplantation in Man 109 
If the antilymphoid serum was absorbed repeatedly with canine kidney or liver cell 
pack, most of the anti-leukocyte titer was removed (5). LEVEY and MEDAWAR (8) have 
~hown that an effective antilymphoid serum can be produced by immunizing the 
heterologous serum donor with epithelial or L-cells. These findings suggest, first, that 
the lymphoid system may be a particularly sensitive target to these agents and, se- 
condly, that the hazard of injury to the kidney or other organs is a real possibility. The 
demonstration of electron dense bodies in the glomeruli of a number of dogs treated 
with ,,antilymphoid" products (5) suggests that a more proper term might be ,,antidog'' 
or ,,antihuman". 
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In spite of this danger, antilymphoid globulin has been well tolerated in animals. 
Even in nontransplanted dogs which were she\-vn to have renal lesions, there was no 
change in kidney function. The reaction of the treated animals was different from that 
of dogs given serum from normal horses (Fig. 5) in that the canine precipitin response 
to horse protein was greatly attenuated. Apparently there is some self-antidotal quality 
of the antilymphoid products as suggested by earlier workers (3, 8)  which reduces its 
hazard. 
Fig. 5 The response of canine precipitin titers to horse protein during daily injection of globu- 
lin prepared from the serum of non-immunized and immunized horses. Note the striking diffe- 
rence in the 2 groups of dogs. (By permission of Surgery, Gynecology iLr Obstetrics, 124 [19671,1) 
Canine Homotra~lsplantation 
Eighteen dogs have received orthotopic liver transplantation while under treatment 
with either intraperitoneal antilymphoid serum (9 animals) or subcutaneous globulin 
(9 animals). No other therapy was used (19). 
Of the 9 animals in the first group, 5, 4, 3, and 2 lived for more than 15, 20, 30, and 
50 days respectively. With limitation of survival credit to 70 days for any dog, the 
mean postoperative survival was 26.8 k 26 (SD) days compared to 6.8 k 3 (SD) days for 
32 untreated controls (p<0.05). Two of these animals are still alive after 5 and 6 
months. One had therapy stopped 3 weeks after transplantation (Fig. 6) and the other 
was treated only prior to operation (Fig. 7). The succes or failure of an experiment was 
not correlated with the presence or absence of lymphopenia. 
Also limiting individual survival credit to 70 days, the results with subcutaneous 
globulin therapy were similar (19), with a mean survival of 36 k 30 (SD) days. Of these 
9 dogs, 5, 5, 4, and 4 lived for more than 15, 20, 30, and 50 days. The prolongation of 
life was significant (p<0.01). Maximum survival in a dog still living is 4 months. 
Tlie ~ r o s ~ e c t s  of Successful Liver Transplantation in Man 111 
A definite protective effect upon renal homografts was also demonstrated in a much 
larger series of renal homotransplantations (19), but not to the same degree as in the 
livers. Not only was the mean survival lower, but the degree of histologic damage was 
more severe and acute even long after operation. These findings suggested, as did an 
earlier study on azathioprine (16), that the liver may actually be a more favorable or- 
gan than the kidney in term of the inherent ease with which it can be shielded from 
immunologic repudiation. The experiments with kidneys (19) also clearly showed that 
treatment for some days before as well as after operation was distinctly superior to 
that started on the day of transplantation. 
Fig. 6 A chronically surviving dog which was treated before and for 20 days after orthotopic 
liver transplantation with intraperitoneal antilymphoid serum (ALS). Note the pronounced lym- 
phocytosis late in the postoperative period. The animal is in excellent health after almost 6 
months. (By permission of Surgery, Gynecology G Obstetrics, 124 [1967], 38) 
Clinical Use of Antilymphoid Globulin 
The foregoing canine studies provided firm guidelines for clinical application. First, 
although the immunosuppressive action of antilymphoid globulin was unequivocal, its 
effect in individual experiments was unpredictable and somewhat weaker than that 
known to be attainable with azathioprine. Secondly, the genuine threat of serum sick- 
ness might limit its use to relatively short periods. Consequently, the globulin was added 
as an adjuvant to the basic regimen of azathioprine and prednisone, after first obtaining 
evidence that it would not cancel the efficacy of the standard drugs. 
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A detailed analysis of these results has been presented elsewhere (19), but some sum- 
mary comments follow. There were 8 newly transplanted patients who received intra- 
muscular antilymphoid globulin beginning from 5 to 35 days before renal homotrans- 
plantation and continuing thereafter as shown in Figure 8. All 8 patients are well after 
9 %  to 14 weeks. Their average daily doses of azathioprine and prednisone as well as 
their BUN'S and creatinine clearances for the first 63 postoperative days are summari- 
zed in Figure 9 and compared to the data of 3 previous series of comparable patients. 
The patients in the antilympoid globulin series required considerably less than half the 
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steroid therapy than any of the 3 preceding groups. They were also given smaller quan- 
tities of azathioprine. This relaxation of standard immunosuppressive therapy was not 
paid for with a loss of renal function. The pooled BUN'S and creatinine clearances in 
the first 3 series were not significantly different from those in the test group. 
Three other patients with progressively failing late renal homografts were placed on 
antilymphoid globulin therapy, after which prednisone dosage was rapidly reduced to 
' 1 2  to ' 1 s  of the original level. Two of these 3 patients had stabilization or improvement 
of renal function in the ensuing 10 and 13 weeks. The third patient, whose BUN and 
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creatinine clearance were 115 and 5 mllminute respectively had a slight further de- 
terioration. She died rather suddenly 13 weeks later of a cardiac arrest which followed 
a bout of acute pulmonary edema. 
Serious systemic toxicity has not yet been observed, although moderate fever has 
been common. Hemagglutinin titers against sheep red cells and precipitin titers rose 
slightly in most patients but with a later tendency to decline (Fig. 8). 
GROUP 1 25 PATIENTS GROUP 3 22 PATIENTS 
GROUP 2 13 PATIENTS GROUP 4 8 PATIENTS 
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Fig. 9 Variations in immunosuppression and renal function during the first 63 postoperative 
days in 4 successive groups of patients who received kidneys from blood relatives. Since the 
blood urea nitrogen and creatinine clearance were not determined each day, these were com- 
piled on a weekly basis. Those in Series 4 received adjuvant therapy with antilymplioid globulin. 
Note the drastic reduction in average prednisone dose which was achieved in these patients 
without significant loss of renal function. The progressive diminution of azathioprine dosage 
in the succeeding series is evident. (By permission of Surgery, Gynecology iL Obstetrics, 124 
[1967], 38) 
Discussion 
Early experience with antilymphoid globulin has awakened hopes that it can be used 
in a safer and more effective program of immunosuppressioi~, which could be applied to 
the problem of homotransplantation of the liver. Tested as the sole therapy in canine 
hepatic homotransplantation, it allows a definite prolongation of life. In a clinical trial 
with renal homotransplantation, it has seemed to permit effective therapy with smaller 
doses of prednisone and azathioprine than had been previously possible. 
I t  has been pointed out to us by Dr. I<. A. PORTER of London, who examined all the 
tissues from our studies, that this hope may be fleeting in view of the report by PARO 
NETTO and Popper (14). These authors showed a synergistic effect of horse serum upon 
the minor hepatotoxicity produced with the appropriate dose of halogenated hydro- 
carbons. If azathioprine damages the human liver, a question which has not yet been 
decisively resolved, the same risk could be expected in man. 
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In any case, it is important to stress the experimental nature of antilymphoid globulin 
therapy in view of the unknown risk from serum sickness. The magnitude of this hazard 
and the related question of nephrotoxicity can be completely assessed only with further 
observation and by study of renal homograft biopsies in those patients now under treat- 
ment. Wider clinical trial is not recommended until this information has been obtained. 
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